Skip to NavigationSkip to content

antimicrobial resistance

Is Pharma doing enough on sustainability?

Published on 20/07/20 at 03:06pm

Adoption of sustainable practices in pharmaceutical operations is ticking along, but given the environmental and health risks if this is not implemented as a matter of urgency, is progress coming fast enough? Matt Fellows investigates what measures pharma firms are taking in line with current guidance.

Industry comes together to form the AMR Action Fund, pledging $1bn to fight antimicrobial resistance

Over 20 biopharma firms have come together to launch the AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), with a goal to deliver between two and four new antibiotic therapies by 2030 in a bid to tackle the growing threat of antibiotic resistance (AMR).

The fund has so far raised almost $1 billion to support clinical research with further investment planned, and will link up with a range of players including development banks, philanthropies and multilateral organisations to this end.

The global rise in antibiotic resistance threatens infection prevention and cure

Published on 20/05/19 at 01:23pm

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional incentivisation initiatives needed to promote innovation, as well as the role of preventative antimicrobial treatments as an important element of this global fight against AMR.

AMR advisor calls for public utility company to tackle AMR

Lord Jim O’Neill, an economist and former government advisor on antimicrobial resistance (AMR), has accused the pharmaceutical industry of “spewing out nonsense” when it comes to tackling the threat of AMR.

“If the pharma companies delivered one tenth of the commitment in their words, we might be getting somewhere,” Lord O’Neill said to reporters in London as he accused the pharmaceutical industry of producing “endless talk and no action” when it comes to AMR.

Destiny Pharma secures £1.6m grant to fight 'superbugs' and antimicrobial resistance

UK biotech Destiny Pharma has secured £1.6 million in funding to further its research into the prevention and elimination of life-threatening “superbugs” without contributing to the threat of antimicrobial resistance (AMR), it has emerged.

The grant was supplied by a collaboration established as part of the UK-China AMR fund, which was itself set up by Innovate UK and the Department of Health and Social Care with the Chinese Ministry of Science and Technology.

AMR superbugs expected to kill 90,000 Britons in the next 30 years

Antibiotic resistant superbugs will kill more than 90,000 British people over the next thirty years if action is not taken to halt rise of antimicrobial resistance (AMR), a report published by the Organisation for Economic Co-operation and Development (OECD) has warned.

Meanwhile AMR bugs will kill an estimated 2.4 million in Europe, North America and Australia by 2050, unless more is done.

UK government accused of using Brexit to avoid antimicrobial resistance ruling

The British government has been accused of using Brexit to avoid implementing new EU legislation preventing powerful antibiotics from be used in farming.

The new rules, designed as part of an effort to tackle antimicrobial resistance, are set to be implemented after Brexit day in March 2019.   However British newspaper The Guardian has revealed that government animal health experts are advising vets and farmers that the changes do not have to be implemented in the UK.

Trump administration resists WHO efforts to tackle antimicrobial resistance

Image Credit: Gage Skidmore

The Trump administration is in the process of drafting an alternative to the World Health Organization’s guidelines on the use of antimicrobial drugs in food producing animals. In resisting the WHO guidelines, which are intended to combat antimicrobial resistance, the move seems to benefit agribusiness.

The WHO guidelines, released in November, recommend that fewer antimicrobial drugs be given to food producing animals and call for the restriction of the use of all medically important antimicrobial drugs in livestock.

Top Ten most popular articles on Pharmafile.com this week

With the UK in the grip of a record-breaking heatwave, it's hard to focus on much else over here, but it's been another packed week in the pharma industry.

The Brexit farce continues as the UK Government has admitted that the NHS will need to stockpile medicines in the event no deal can be reached with the EU on an exit deal, and Roche and AstraZeneca have followed in Pfizer's footsteps with pledges to pause price hikes until 2019, after the latter firm was chastised over social media by President Donald Trump.

But the most-read story this week is the heart-breaking news th

The mission against antimicrobial resistance

Published on 23/07/18 at 11:39am
Image Credit: Dr Graham Beards at en.wikipedia

Two headlines have highlighted the ‘here and now’ of the threat of rising antimicrobial resistance (AMR), writes Dr Peter Jackson.

A study reported in The Lancet Infectious Diseases found that antibiotics are now failing to work in a fifth of patients who suffer an infection after hospital surgery.

This global research, looking at 13,000 patients across 66 countries, found that over 12% of those undergoing procedures developed a post-operative surgical site infection (SSI). 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches